VIRTUAL EVENT

2 - 4 DEC 2020

LONDON 2020

Save the date:

The Virtual E-Cigarette Summit, 2-4 December 2020

 

Science, Regulation and Public Health

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life.  Despite decades of tobacco control efforts and public health education on the harms of smoking, the decline in smoking rates has been frustratingly slow.

The growth of e-cigarette over the last 6-7 years can best be viewed as an unfolding phenomenon.  The public health response has ranged from enthusiastic support to vigorous opposition as scientists and regulators grapple to find the most appropriate response.  Their verdicts will probably feature among the key public health decisions of our time.

The much anticipated NASEM report published earlier this year, supported the PHE and Royal College of Physicians findings that e-cigarettes posed a fraction of the risk to combustible tobacco. The report highlighted that the public health impact of e-cigarettes will depend on the balance of 3 factors i) The ability to help current smokers quit ii) The potential to increase adolescents’ use of combustible cigarettes iii) Any inherent toxicity of e-cigarettes themselves.

The E-Cigarette Summit provides a much needed neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.

WHAT QUESTIONS WILL BE EXPLORED?

 

The E-Cigarette Summit will include high level briefings from experts and encourages interaction through panel debates and open floor discussions.  Questions will be explored in a balanced and objective environment allowing attendees to build their knowledge and share their viewpoints. The E-Cigarette Summit will explore the latest research and evidence on the following areas:

  • SCHEER report – does the evidence support the findings – What next for the TPD in Europe?
  • What are the likely impacts of PMTA regulatory process in America?
  • Has the Swedish experience with SNUS been considered a success for public health?
  • The UK policy on THR and tobacco control – post Brexit
  • Australia has one of the strictest tobacco control programmes in the world and is now taking one of the harshest measures to prevent e-cigarettes.
  • Nicotine as a stand-alone product – perceptions of harms and benefits
  • Do nicotine limits in Europe protect health?
  • Understanding the Toxicology report on e-cigarettes – questions and answers
  • Cardiovascular and Respiratory communities at a cross roads
  • E-cigarette use and cardio vascular disease, understanding the available studies and the associations.
  • Coverage of e-cigarettes in National News – how scientists influence the debate
  • Has the uniquely lethal nature of combustibles been drowned out in the divisive THR debate?
  • Cochrane review of E-Cigarettes and cessation
  • Stop smoking services and the impact that e-cigarettes have had on NRT and behavioural programmes
  • Do flavour bans protect youth?
  • Should concerns about youth take a moral precedence over smoking adults?
  • The scientific underpinning of UK policy on THR in context of an evolving evidence base
  • The importance of maintaining Integrity in science for tobacco control

CONFIRMED SPEAKERS

The following speakers are confirmed, additional speakers are still being added

  • Prof Alan Boobis, OBE, Emeritus Professor of Toxicology, Imperial College London
  • Tom Sheldon, Senior Press Manager, Science Media Centre
  • Prof Jacob George, Professor of Cardiovascular Medicine and Therapeutics, University of Dundee
  • Jamie Hartmann-Boyce, Senior Researcher, Health Behaviours & Managing Editor, Cochrane Tobacco Addiction Group
  • Dr Sanjay Agrawal, University Hospital Leicester NHS Trust
  • Prof Ann McNeill, Professor of Tobacco Addiction, UK Centre for Tobacco & Alcohol Studies, Kings College London
  • Dr Karl E. Lund, Senior Researcher, Norwegian Institute of Public Health
  • Prof Linda Bauld, Professor of Health Policy, University of Stirling and UK Centre for Tobacco & Alcohol Studies
  • Deborah Arnott, Chief Executive, Action on Smoking and Health
  • Clive Bates, Director, Counterfactual Consulting Ltd
  • Martin Dockrell, Tobacco Control Lead, Public Health England
  • Tim Phillips, Managing Director, ECigIntelligence
  • Louise Ross, NNA
  • Prof Robert West, Professor of Health Psychology & Director of Tobacco Studies
  • Prof Ken Warner, Professor, Health Management & Policy
  • Prof Thomas J. Glynn, PhD, Consulting Professor, Stanford Prevention Research Center

WHO SHOULD ATTEND

In particular, this event will be relevant to:

  • Regulators and policy advisors
  • Scientific/research community
  • Smoking cessation practitioners/services
  • Health charities and health campaigners
  • Public health professionals and academics
  • Medical professionals
  • Industry stakeholders

The Summit independently provides hosted places for vapers and individuals without funding to attend, but are important stakeholders in the harm reduction debate .  These places are discretionary and are considered on a case by case basis.  If you would like to find out more please contact us.